药品名称：注射用硫酸艾沙康唑 证券代码：600056 证券简称：中国医药 公告编号：临 2026-021 号 中国医药健康产业股份有限公司 关于子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，中国医药健康产业股份有限公司（以下简称"公司"）下属全资子公 司海南通用三洋药业有限公司（以下简称"三洋药业"）收到国家药品监督管理 局（以下简称"国家药监局"）核准签发的注射用硫酸艾沙康唑（以下简称"该 药品"）《药品注册证书》，现将有关情况公告如下： 一、注册证书基本信息 受理号：CYHS2401052、CYHB2501689 证书编号：2026S00634 剂型：注射剂 规格：0.2g（按 C22H17F2N5OS 计） 注册分类：化学药品 4 类 上市许可持有人：海南通用三洋药业有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品相关情况 （一）注射用硫酸艾沙康唑主要适用于治疗成人患者的侵袭性曲霉病和侵袭 性 ...

证券代码：600056 证券简称：中国医药 公告编号：临 2026-020 号 中国医药健康产业股份有限公司 关于子公司获得药品补充申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，中国医药健康产业股份有限公司（以下简称"公司"）下属全资子公 司天方药业有限公司（以下简称"天方药业"）收到国家药品监督管理局（以下 简称"国家药监局"）核准签发的两份米诺地尔搽剂（以下简称"该药品"）《药 品补充申请批准通知书》，该药品上市许可持有人由海南广升誉制药有限公司变 更为天方药业。现将有关情况公告如下： 一、通知书基本信息 药品名称：米诺地尔搽剂 证书编号：2026B01226、2026B01227 剂型：搽剂 规格：5%（60ml：3.0g）、2%（60ml：1.2g） 注册分类：化学药品 上市许可持有人：天方药业有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 此次申请事项符合药品注册的有关要求，同意按照《药品上市后变更管理办法（试 行）》相关规定，批准本品上市许可持有人由"海南 ...

Core Viewpoint - The company has provided a guarantee of up to 100 million yuan for its subsidiary, Nanhua General, to facilitate its business operations, which is deemed necessary for the subsidiary's development and financial needs [1][4]. Summary by Sections Guarantee Details - The company issued an irrevocable maximum guarantee letter to China Merchants Bank, Nanchang Branch, for Nanhua General to handle commercial bills, letters of credit, and guarantees, with a maximum amount of 100 million yuan [1][2]. - The company holds a 49% stake in Nanhua General, with a voting power of 51%, making it a controlling company [1]. Internal Decision-Making Process - The board of directors approved the guarantee during meetings held on April 24, 2025, and May 16, 2025, with a total guarantee limit for the year 2025 set at 692 million yuan, including the 100 million yuan for Nanhua General [1][5]. Necessity and Reasonableness of the Guarantee - The guarantee is necessary for Nanhua General's business operations, and the company can monitor its financial status and performance. Additionally, minority shareholders of Nanhua General have provided counter-guarantees through equity pledges, making the risk manageable [4]. Board of Directors' Opinion - The board believes that the guarantee aligns with the company's operational needs and will support Nanhua General's funding requirements, ensuring sustainable business development without adverse effects on the company's operations [5]. Cumulative Guarantee Situation - As of the announcement date, the total guarantees provided by the company to its subsidiaries amount to 300 million yuan, which is 2.54% of the company's audited net assets for 2024. The actual outstanding guarantees amount to 18.0715 million yuan, representing 0.15% of the audited net assets for 2024, with no overdue guarantees reported [5].

证券代码：600056 证券简称：中国医药 公告编号：临 2026-019 号 中国医药健康产业股份有限公司 关于为控股公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 根据统筹考虑授信资源的安排，结合控股公司实际业务需要，中国医药健康 产业股份有限公司（以下简称"公司"）向招商银行股份有限公司南昌分行出具 《最高额不可撤销担保书》，为南华通用办理商业汇票、信用证和保函/票据保 付等业务提供担保，本次担保最高额金额为 10,000 万元。公司持有南华通用 49% 股权，按照公司章程约定，表决权比例为 51%，南华通用系公司控股公司。 担保对象及基本情况 | | 被担保人名称 本次担保金额 | 10,000.00 | 万元 | 江西南华（通用）医药有限公司（以下简称"南华通用"） | | --- | --- | --- | --- | --- | | 担保 | | | | | | 对象 | 实际为其提供的担保余额 | 1,807.15 | 万元 | | | | 是否在前期预计额度内 | 是 | ...

Core Viewpoint - China National Pharmaceutical Group announced that its wholly-owned subsidiary, Kangli Pharmaceutical, has received approval from the National Medical Products Administration for the injection of phosphoric acid teicoplanin, expanding the company's product line [1] Group 1: Product Approval - The approved drug is indicated for the treatment of acute bacterial skin and skin structure infections, with a specification of 200mg [1] - The registration application was accepted by the National Medical Products Administration in September 2024, with a total investment of approximately 12.74 million yuan as of the announcement date [1] Group 2: Market Context - A total of 18 manufacturers in China have passed or are deemed to have passed the consistency evaluation for this drug [1] - The estimated sales revenue for public hospitals and grassroots medical terminals in China for this drug is approximately 1.16 million yuan in 2024, indicating a potential market presence [1]

Policy Developments - Shandong Province held a meeting on February 25, 2026, to address corruption and misconduct in the healthcare sector, emphasizing the need for a coordinated effort to safeguard medical insurance funds and promote orderly development in healthcare [1] Drug and Device Approvals - Kanghong Pharmaceutical received approval from the National Medical Products Administration for clinical trials of KHN707 tablets for insomnia, a class 1 innovative drug [2] - Fosun Pharma's subsidiary received approval for clinical trials of Rumaine® (generic name: Luwomeitini tablets) for advanced non-small cell lung cancer, with global sales of MEK1/2 inhibitors projected to reach approximately $2.068 billion in 2024 [3] - China Pharmaceutical announced that its subsidiary received a drug registration certificate for injectable fosfomycin, aimed at treating acute bacterial skin and soft tissue infections [4] - Huyou Pharmaceutical received FDA approval for its new drug applications for Etoposide injection and Fluorouracil injection, enabling sales in the U.S. market [5] - Kangfang Biotech's application for the monoclonal antibody AK120 was accepted for review by the National Medical Products Administration [6] Industry Developments - Junshi Bioscience and Deqi Pharmaceuticals entered a strategic collaboration to explore the combined treatment potential of JS207 and ATG-037 for cancer patients in mainland China [8] - Illumina announced an 18-month innovation upgrade roadmap for the NovaSeq X sequencer, enhancing its capabilities and productivity [9] Capital Market Activities - Sainuo Medical announced a share repurchase plan with a total amount between 15 million and 30 million yuan, aimed at employee stock ownership plans or equity incentives [10] Financial Data - United Imaging reported a net profit of 1.888 billion yuan for 2025, a year-on-year increase of 49.60%, driven by new product launches and growth in overseas business [11] - Xiansheng Pharmaceutical projected a revenue of approximately 7.7 billion to 7.8 billion yuan for the 2025 fiscal year, with a net profit increase of 80.1% to 93.9% [12] - Sainuo Medical reported a net profit of 47.29 million yuan for 2025, a significant increase of 3,057.05% year-on-year, attributed to revenue growth and cost management [13]

Group 1: Financial Performance Highlights - Lante Optics achieved a revenue of 1.536 billion yuan in 2025, a year-on-year increase of 48.52%, with a net profit of 388 million yuan, up 76.09% [1] - United Imaging reported a revenue of 13.82 billion yuan for 2025, reflecting a 34.18% year-on-year growth, and a net profit of 1.888 billion yuan, up 49.60% [2] - Hengxuan Technology's revenue reached 3.525 billion yuan, an 8.02% increase, with a net profit of 588 million yuan, up 27.75% [3] - Nanya New Materials reported a significant net profit increase of 378.65%, reaching 241 million yuan, with revenue of 5.228 billion yuan, up 55.52% [4] - Yancoal Australia, a subsidiary of Yancoal Energy, reported a revenue of 5.949 billion AUD and a net profit of 4.4 billion AUD for 2025 [5] - Hanlan Co. reported a revenue of 10.467 billion yuan, a 13.04% increase, but a net profit decline of 9.59% to 592 million yuan [10][11] - Transsion Holdings experienced a revenue decline of 4.50% to 65.623 billion yuan, with a net profit drop of 53.43% to 2.584 billion yuan [14] - Huachuang Technology achieved a revenue of 628 million yuan, a 2.78% increase, with a net profit of 42.678 million yuan, up 89.45% [21] - Aiko Optoelectronics reported a revenue of 440.311 million yuan, a 77.36% increase, with a net profit of 64.0919 million yuan, up 307.63% [34] - Chip Microelectronics achieved a revenue of 1.408 billion yuan, a 47.61% increase, with a net profit of 290 million yuan, up 80.42% [35] - Shenkong Co. reported a revenue of 443 million yuan, a 46.26% increase, with a net profit of 101 million yuan, up 146.54% [36] - Qinda Environmental reported a revenue of 2.042 billion yuan, a 55.42% increase, with a net profit of 181 million yuan, up 94.62% [39] Group 2: Corporate Developments - Huilong New Materials announced that its actual controller is planning a significant matter that may lead to a change in company control, resulting in a stock suspension [6] - Fangzheng Securities disclosed that its shareholder China Cinda did not reduce its shareholding as planned during the designated period [7] - Lingyi Technology plans to invest 20 million yuan in a partnership with several investment firms [8] - Longbai Group's subsidiary has partially resumed production after a safety incident [9] - Fuda Co. plans to reduce its repurchased shares by up to 1% through centralized bidding [13] - Fuxing Pharmaceutical's subsidiary received approval for clinical trials of a new drug for lung cancer [15] - Beixin Road and Bridge won a bid for a highway reconstruction project worth 751 million yuan [16] - Songsheng Co. established a joint venture with a registered capital of 30 million yuan, focusing on digital energy products [17] - Moxinlin reported a revenue of 577 million yuan, a 20.98% increase, with a net profit of 55.8745 million yuan, up 22.69% [18] - Zhuhai Beer reported a revenue of 5.878 billion yuan, a 2.56% increase, with a net profit of 903 million yuan, up 11.42% [24] - Honghua Digital reported a revenue of 2.308 billion yuan, a 28.90% increase, with a net profit of 529 million yuan, up 27.63% [25] - Xinfeng Pharmaceutical received FDA approval for two injectable drugs [26] - Jiazhe New Energy's project for green hydrogen production received regulatory approval [27] - Chip Microelectronics reported a revenue of 5.24 billion yuan, a 29.48% increase, with a net profit of 302 million yuan, up 36.1% [28] - Debang Co. completed the cash settlement process for its delisting [29] - Xingfu Electronics reported a revenue of 1.475 billion yuan, a 29.72% increase, with a net profit of 208 million yuan, up 30.37% [30] - Longda Food announced the resignation of its general manager due to work adjustments [31] - Bohai Chemical reported that some fundraising projects have commenced production [32] - Shengke Communication reported a net loss of 150 million yuan for 2025 [33] - Jin Cheng Pharmaceutical's subsidiaries received drug registration certificates for two products [37] - Jinpu Titanium Industry announced the resumption of production at its subsidiary [38] - Zhigao Electric's subsidiary won a bid for a project worth 182 million yuan [40]

Core Viewpoint - China Medical (600056.SH) announced that its wholly-owned subsidiary, Hainan Tongyong Kangli Pharmaceutical Co., Ltd. (referred to as "Kangli Pharmaceutical"), has received a drug registration certificate from the National Medical Products Administration for injectable fosfomycin trometamol, which is primarily used for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by Gram-positive bacteria sensitive strains [1] Group 1 - The drug registration certificate was officially issued by the National Medical Products Administration [1] - Injectable fosfomycin trometamol is indicated for treating infections caused by Gram-positive bacteria [1] - The approval represents a significant milestone for Kangli Pharmaceutical in expanding its product offerings [1]

证券代码：600056 证券简称：中国医药 公告编号：临 2026-018 号 中国医药健康产业股份有限公司 关于子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，中国医药健康产业股份有限公司（以下简称"公司"）下属全资子公 司海南通用康力制药有限公司（以下简称"康力药业"）收到国家药品监督管理 局（以下简称"国家药监局"）核准签发的一份注射用磷酸特地唑胺（以下简称 "该药品"）《药品注册证书》，现将有关情况公告如下： 一、注册证书基本信息 药品名称：注射用磷酸特地唑胺 二、药品其他相关情况 （一）注射用磷酸特地唑胺主要适用于治疗由革兰氏阳性菌敏感株引起的急 性细菌性皮肤及皮肤软组织感染（ABSSSI）。 （二）国家药监局于 2024 年 9 月受理该药品的注册申请。 （三）截至本公告披露日，该药品累计相关投入约 1,274 万元人民币（未经 审计）。 （四）药品市场情况介绍 经查询国家药监局网站显示，截至本公告披露日，国内已有扬子江药业集团 有限公司、瑞阳制药股份有限公司、南京正大天晴制药有 ...

Core Viewpoint - China Medical announced that its wholly-owned subsidiary, Kangli Pharmaceutical, received approval from the National Medical Products Administration for the injection of Phosphate Tedizolid, which is intended for the treatment of acute bacterial skin and skin structure infections [1] Group 1: Product Approval - The drug is approved for treating acute bacterial skin and skin structure infections with a specification of 200mg [1] - The registration application was accepted by the National Medical Products Administration in September 2024, with a total investment of approximately 12.74 million yuan as of the announcement date [1] Group 2: Market Context - A total of 18 manufacturers in China have passed or are deemed to have passed the consistency evaluation for this drug [1] - The estimated sales revenue for public hospitals and grassroots medical terminals in China for 2024 is approximately 1.16 million yuan [1] Group 3: Implications for the Company - The approval enriches the company's product line, but future sales of the drug may not meet expectations [1]